On May 1, 2026, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (VEPPANU®, ARV-471), an oral estrogen receptor (ER) degrader co-developed by Arvinas and Pfizer, with global development, manufacturing, and commercialization rights licensed to Rigel Pharmaceuticals, for adult patients with ESR1-mutated, ER-positive / HER2-negative advanced or metastatic breast cancer. The approval was issued approximately five weeks ahead of the assigned PDUFA date of June 5, 2026, and carries singular historical significance: vepdegestrant is the first PROTAC (PROteolysis TArgeting Chimera) therapeutic ever approved by the FDA. This article summarizes the pivotal VERITAC-2 trial, efficacy and safety outcomes, and the regulatory and clinical implications.
Target Patient Population
- Adults (≥18 years) with advanced or metastatic breast cancer
- ER-positive / HER2-negative
- Documented ESR1 mutation by an approved test (anticipated to be a liquid biopsy ctDNA assay)
- Disease progression after prior endocrine-based therapy
- Oral formulation, once daily
Pivotal Trial Overview
The approval is based on the VERITAC-2 trial (NCT05654623), a global, randomized, open-label, controlled Phase 3 study in ER+/HER2- advanced or metastatic breast cancer following progression on prior endocrine-based therapy that included a CDK4/6 inhibitor.
| Item | VERITAC-2 detail |
|---|---|
| Trial ID | NCT05654623 |
| Design | Randomized, open-label, controlled, Phase 3 |
| N | Approximately 624 (ITT); roughly half with ESR1 mutation |
| Population | ER+/HER2- advanced/metastatic breast cancer progressing on ≥1 prior endocrine line including a CDK4/6 inhibitor |
| Intervention | Vepdegestrant 200 mg orally once daily |
| Comparator | Fulvestrant 500 mg intramuscular (standard of care) |
| Primary endpoint | Progression-free survival (PFS, blinded independent central review) — hierarchical testing in ESR1-mutated and ITT populations |
| Key secondary endpoints | OS, ORR, duration of response (DoR), patient-reported outcomes, safety |
Vepdegestrant belongs to the bifunctional small-molecule class known as PROTACs. The molecule binds the target (ER, in this case) at one end and an E3 ubiquitin ligase (cereblon) at the other, bringing the two into proximity and inducing ubiquitination followed by proteasomal degradation. Whereas conventional SERDs such as fulvestrant promote ER degradation through binding-induced conformational instability, PROTACs are catalytic in mechanism — recycling the ligase to act on multiple ER copies — which in principle allows deeper ER depletion at lower drug exposures. This approval marks the first translation of that mechanistic premise into a clinically validated, regulator-approved therapy.
Key Efficacy Results
Initial VERITAC-2 data were presented at ASCO 2025 and published in The New England Journal of Medicine. Outcomes diverged sharply between the ESR1-mutated and ITT populations.
| Endpoint | ESR1-mutated population | ITT population |
|---|---|---|
| Median PFS (vepdegestrant) | ~5.0 months | ~3.7 months |
| Median PFS (fulvestrant) | ~2.1 months | ~3.6 months |
| Hazard ratio (HR) | 0.57 (statistically significant) | 0.83 (not statistically significant) |
| p-value | p < 0.001 | NS |
The primary endpoint was tested hierarchically, beginning with the ESR1-mutated population, where vepdegestrant delivered a statistically significant and clinically meaningful PFS improvement. Significance was not crossed in the ITT population, and the FDA-approved indication is consequently restricted to ESR1-mutated disease. This restriction follows the now-familiar precision-oncology approval pattern: the agency confines the labeled indication to the population where the confirmatory hierarchy actually delivered statistical significance.
Secondary endpoints — including ORR and clinical benefit rate — also numerically favored vepdegestrant in the ESR1-mutated subset, and patient-reported QoL was non-inferior to fulvestrant. Overall survival data remain immature and will be reported at later analyses.
Safety Profile
The VERITAC-2 safety profile is broadly manageable and characteristic of endocrine-based therapy. PROTAC-specific safety monitoring will continue post-approval.
| Adverse Event | All grades | Grade ≥3 |
|---|---|---|
| Fatigue | ~25% | <2% |
| Nausea | ~20% | <1% |
| Diarrhea | ~15% | <1% |
| ALT/AST elevation | ~10% | 2–3% |
| Arthralgia | ~10% | <1% |
| QT prolongation | Mild | Rare |
The label does not carry a Boxed Warning, and no REMS program is required. Grade ≥3 adverse events leading to discontinuation occurred at rates comparable to, or marginally lower than, fulvestrant. Because vepdegestrant engages the cereblon E3 ligase — the same target exploited by the thalidomide class of immunomodulatory imides — long-term hematologic and reproductive safety signals will remain a subject of post-marketing surveillance.
Regulatory and Clinical Significance
The significance of this approval can be organized across three axes: drug-class, treatment-mapping, and industry-structure.
(1) A drug-class inflection point: the first PROTAC. The PROTAC concept was articulated by Craig Crews (Yale) and Raymond Deshaies in the early 2000s, and the industry has spent a quarter-century waiting for the first approval to validate the modality. With this approval, PROTACs move from proof-of-concept to a clinically effective, regulatory-approved therapeutic modality. A pipeline of follower programs at Arvinas, Foghorn, C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics and others now operates with a precedent in hand — likely accelerating the broader market for targeted protein degraders.
(2) Positioning in ER+/HER2- advanced breast cancer. After CDK4/6 inhibitor progression, the modern treatment armamentarium includes SERDs (fulvestrant, elacestrant), AKT inhibition (capivasertib), PI3K inhibition (alpelisib), and mTOR inhibition (everolimus combinations). Because vepdegestrant is labeled for ESR1-mutated disease only, its most direct competitor is elacestrant — which holds the same ESR1-mutated indication. The differentiation question — oral once-daily dosing, the catalytic ER-degradation mechanism, and the trajectory of post-CDK4/6 sequencing — will be settled in real-world practice and head-to-head investigator-initiated work.
(3) Industry structure: an Arvinas / Pfizer / Rigel three-party model. Arvinas provided the PROTAC chemistry and early development, Pfizer co-led later-stage development and regulatory engagement, and Rigel Pharmaceuticals received exclusive global development, manufacturing, and commercialization rights. The result is a contemporary case study of how a biotech-originated novel-modality program can reach approval through layered partnerships with both a mega-pharma and a specialist commercializer — a pattern that may recur as more PROTAC and molecular-glue programs mature. Approval status in other jurisdictions is determined separately and should be confirmed via local regulatory authorities.
My Thoughts and Future Outlook
The first PROTAC approval has arrived — meaning the field will no longer ask “when will the first one come?” Targeted protein degradation has crossed from a thought experiment to a clinical proof point. That it landed in breast cancer, one of the most contested therapeutic arenas in oncology, gives every follower program something concrete to work with.
The careful reading, however, is that the ITT population did not reach statistical significance, and the indication is consequently restricted to ESR1-mutated disease. It is too early to generalize that PROTACs outperform SERDs. Whether the mechanistic advantage will translate broadly — perhaps specifically against ESR1-mutated tumors, or perhaps in delayed resistance over long-term dosing — will only be resolved as OS data mature and as follower trials (VERITAC-3, combinations with CDK4/6 or PI3K inhibitors) read out.
From an industry standpoint, the Arvinas / Pfizer / Rigel three-party structure is worth watching. The combination of biotech-originated novel modality, mega-pharma late-stage execution, and specialist commercialization may be the practical value chain for new-modality drugs reaching patients. How this template extends — to other PROTACs, to molecular glues, to next-generation degraders — will shape the rest of the decade in targeted protein degradation.
This article was compiled and summarized by Morningglorysciences based on FDA public materials, the official Arvinas press release, peer-reviewed publications of the VERITAC-2 trial, and related sources. Treatment decisions should always be made in reference to the original publications, the most recent prescribing information, and local clinical practice guidelines.
Comments